Fractional Support as a Service

Embedded expertise for biotech—discovery support, nonclinical strategy, investor‑ready pitch support, and scientific due diligence without the cost of a full‑time hire.

Who we help

  • Early‑stage biotech & platform startups needing a clear nonclinical plan and leadership before hiring in‑house.

  • Discovery‑stage & platform teams rationalizing targets, models, and biomarkers.

  • Academic spinouts translating promising data into development‑quality packages.

  • Investors & venture studios that require independent scientific/technical diligence.

  • Clinical‑adjacent teams tightening nonclinical plans to conserve capital and time.

What you get

Discovery & Translational Support

  • Target identification & prioritization; indication scouting

  • Mechanism‑of‑action & translational hypothesis; decision criteria

  • Assay strategy & screening cascade (in vitro, ex vivo, in vivo)

  • Model selection/validation and biomarker plan (fit‑for‑purpose assays)

  • PK/PD inputs and dose‑selection hypotheses; data standards & power

  • Discovery CRO selection/oversight (biology, DMPK, in vivo pharmacology)

  • Lead optimization guidance; developability & DMPK risk flags

  • Candidate selection criteria mapped to clinical PoM/PoC

Nonclinical Strategy & IND Planning

  • Target Product Profile (TPP) and indication fit

  • Nonclinical roadmap + IND‑enabling study matrix (GLP/GxP aware)

  • Vendor landscape, CRO RFPs, selection, and oversight

  • Risk register with mitigation plan, budget, and 12–18‑month timeline

  • Cross‑functional alignment with CMC, Clinical, and Regulatory

Investor‑Ready Pitch & Fundraising Support

  • Investor narrative and pitch deck development

  • Milestone model, use‑of‑funds, and KPI dashboard

  • Data room structure, checklists, and document QA

  • Coaching for partner/IC meetings and mock diligence

Scientific & Technical Due Diligence (Buy‑ or Sell‑Side)

  • Red‑flag screen → deep dive (program, tox, translational rationale)

  • Feasibility and replication assessment; assumptions and risks

  • Investment/partnership memo with go/no‑go recommendations

Engagement options

1) Fractional Discovery & Translational Advisor
Own target & indication fit, MoA/translational hypothesis, assay & model strategy, screening cascade, and biomarker plan; oversee discovery CROs and decision logs.

2) Fractional Nonclinical Strategy Lead
Own the TPP and roadmap, design IND‑enabling studies, run CRO selection and oversight, maintain risk/budget/milestones, and deliver board‑ready updates.

3) Fractional Investor Readiness Advisor
Craft the story and deck, build the data room, pressure‑test assumptions, and prepare teams for investor meetings.

4) Fractional Diligence Partner
Independent scientific/technical diligence for investors or partners—from screening to written investment memos.

Mix and match packages to support fundraising windows or IND planning sprints.

Outcomes we deliver

  • Clear discovery strategy: target/indication fit, mechanism hypothesis, and screening cascade

  • Validated models and biomarker plan tied to human endpoints

  • Early developability/DMPK risk flags and candidate selection criteria

  • Decision‑grade nonclinical roadmaps tied to a clear TPP and indication rationale

  • IND‑enabling study plans that balance risk, cost, and time

  • Investor‑ready pitch decks and data rooms that withstand scrutiny

  • Independent diligence memos with risks, mitigations, and go/no‑go calls

FAQs

What’s the difference between fractional and hourly consulting?
Fractional = embedded ownership with recurring leadership time; hourly = ad‑hoc advice.

Can you act as Interim Head of Discovery or Nonclinical?
Yes—scope typically includes roadmap, study design, CRO oversight, and cross‑functional alignment (no legal/regulatory representation).

Do you run wet‑lab experiments?
No—we don’t operate a lab. We design studies, select/oversee CROs/academic labs, review protocols and data, and ensure decision‑grade outputs.

Which modalities do you support?
Modality‑agnostic: small molecules, biologics, peptides, RNA/oligo, cell and gene therapies.

Do you mark up vendors?
No. We are vendor‑agnostic and do not take referral fees.

How quickly can we start?
Usually within 1–2 weeks of agreement; we can prioritize urgent diligence windows.

Geography & time zones?
Remote‑first; support roles worldwide.

Confidentiality & conflicts?
We sign mutual NDA, disclose potential conflicts, and avoid competing claims. All deliverables are client‑owned.

Empty modern conference room with large windows, wooden chairs, a long table, a laptop, and a projector on the ceiling.